Keywords: Ipsen, Debipharm, Decapeptyl, prostate cancer, Recordati, silodosin, Prostatic hyperplasia
Ipsen debuts Decapeptyl in France, Recordati gains EU clearance for silodosin
Article | 4 February 2010
French specialty drugmaker Ipsen and Swiss biopharmaceutical group Debiopharm have announced the launch by Ipsen in France of Decapeptyl (triptorelin embonate1) LP 22.5mg six-month sustained-release formulation for the treatment of locally advanced or metastatic hormone-dependent prostate cancer. Other launches are planned shortly, notably in Germany and Portugal.
The marketing authorization (MA) to this formulation of Decapeptyl was granted on November 10, 2009, by the French regulatory authority (Agence Française de Securite Sanitaire des Produits de Sante, AFSSAPS) for the treatment of locally advanced and metastatic hormone-dependent prostate cancer. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
